Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bristol-Myers Squibb Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BMY
New York
2834
https://www.bms.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bristol-Myers Squibb Co
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
- May 3rd, 2024 1:30 pm
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
- May 3rd, 2024 11:15 am
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
- May 3rd, 2024 9:08 am
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
- May 2nd, 2024 2:02 pm
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
- May 1st, 2024 12:00 pm
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
- Apr 30th, 2024 2:36 pm
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
- Apr 30th, 2024 1:00 pm
J&J, Bristol Myers lose challenges to US drug price negotiation program
- Apr 29th, 2024 9:52 pm
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
- Apr 29th, 2024 10:00 am
Repertoire pivot pays dividends with Bristol Myers deal
- Apr 29th, 2024 6:00 am
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Apr 27th, 2024 1:48 pm
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
- Apr 26th, 2024 12:25 pm
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
- Apr 26th, 2024 10:59 am
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
- Apr 26th, 2024 5:08 am
Q1 2024 Bristol-Myers Squibb Co Earnings Call
- Apr 26th, 2024 2:39 am
Bristol Myers Squibb stock tumbles on cost-cutting initiative
- Apr 25th, 2024 8:41 pm
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
- Apr 25th, 2024 8:01 pm
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
- Apr 25th, 2024 6:28 pm
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
- Apr 25th, 2024 6:23 pm
Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall
- Apr 25th, 2024 4:08 pm
Scroll